Cargando…

Stimulatory effect of imeglimin on incretin secretion

AIMS/INTRODUCTION: Imeglimin is a new antidiabetic drug structurally related to metformin. Despite this structural similarity, only imeglimin augments glucose‐stimulated insulin secretion (GSIS), with the mechanism underlying this effect remaining unclear. Given that glucose‐dependent insulinotropic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yingyue, Quan, Sugawara, Kenji, Takahashi, Harumi, Yokoi, Norihide, Ohbayashi, Kento, Iwasaki, Yusaku, Seino, Susumu, Ogawa, Wataru
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10204172/ https://www.ncbi.nlm.nih.gov/pubmed/36977210 http://dx.doi.org/10.1111/jdi.14001

Ejemplares similares

β‐Cell glutamate signaling: Its role in incretin‐induced insulin secretion
por: Yokoi, Norihide, et al.
Publicado: (2016)

Essential roles of aspartate aminotransferase 1 and vesicular glutamate transporters in β-cell glutamate signaling for incretin-induced insulin secretion
por: Murao, Naoya, et al.
Publicado: (2017)

Glutamate Acts as a Key Signal Linking Glucose Metabolism to Incretin/cAMP Action to Amplify Insulin Secretion
por: Gheni, Ghupurjan, et al.
Publicado: (2014)

Effects of imeglimin on mitochondrial function, AMPK activity, and gene expression in hepatocytes
por: Hozumi, Kaori, et al.
Publicado: (2023)

Glutamate as intracellular and extracellular signals in pancreatic islet functions
por: TAKAHASHI, Harumi, et al.
Publicado: (2019)

Tumor‐like features of gene expression and metabolic profiles in enlarged pancreatic islets are associated with impaired incretin‐induced insulin secretion in obese diabetes: A study of Zucker fatty diabetes mellitus rat
por: Hayami, Tomohide, et al.
Publicado: (2020)

Comparison of incretin immunoassays with or without plasma extraction: Incretin secretion in Japanese patients with type 2 diabetes
por: Yabe, Daisuke, et al.
Publicado: (2011)

Glutamate is an essential mediator in glutamine‐amplified insulin secretion
por: Han, Guirong, et al.
Publicado: (2021)

Increased glycolysis affects β-cell function and identity in aging and diabetes
por: Murao, Naoya, et al.
Publicado: (2021)

A Novel Diphenylthiosemicarbazide Is a Potential Insulin Secretagogue for Anti-Diabetic Agent
por: Sugawara, Kenji, et al.
Publicado: (2016)

Meal sequence and glucose excursion, gastric emptying and incretin secretion in type 2 diabetes: a randomised, controlled crossover, exploratory trial
por: Kuwata, Hitoshi, et al.
Publicado: (2015)

Gastrointestinal Distension by Pectin-Containing Carbonated Solution Suppresses Food Intake and Enhances Glucose Tolerance via GLP-1 Secretion and Vagal Afferent Activation
por: Ohbayashi, Kento, et al.
Publicado: (2021)

Phase 2 trial with imeglimin in patients with Type 2 diabetes indicates effects on insulin secretion and sensitivity
por: Theurey, Pierre, et al.
Publicado: (2022)

Pharmacokinetics of Imeglimin in Caucasian and Japanese Healthy Subjects
por: Fouqueray, Pascale, et al.
Publicado: (2022)

Establishment of new clonal pancreatic β‐cell lines (MIN6‐K) useful for study of incretin/cyclic adenosine monophosphate signaling
por: Iwasaki, Masahiro, et al.
Publicado: (2010)

Molecular mechanisms of incretin hormone secretion()
por: Ezcurra, Marina, et al.
Publicado: (2013)

A novel mechanism of imeglimin‐mediated insulin secretion via the cADPR‐TRP channel pathway
por: Funazaki, Shunsuke, et al.
Publicado: (2021)

Molecular Mechanisms by Which Imeglimin Improves Glucose Homeostasis
por: Yaribeygi, Habib, et al.
Publicado: (2020)

Reduced lactic acidosis risk with Imeglimin: Comparison with Metformin
por: Theurey, Pierre, et al.
Publicado: (2022)

Effects of the anti-diabetic imeglimin in hyperglycemic mice with septic shock
por: Wagner, F, et al.
Publicado: (2012)

Nutrient detection by incretin hormone secreting cells
por: Diakogiannaki, Eleftheria, et al.
Publicado: (2012)

The mechanism by which imeglimin inhibits gluconeogenesis in rat liver cells
por: Vial, Guillaume, et al.
Publicado: (2021)

Imeglimin‐mediated glycemic control in maternally inherited deafness and diabetes
por: Ishibashi, Ryoichi, et al.
Publicado: (2023)

Glucose-Lowering Effects of Imeglimin and Its Possible Beneficial Effects on Diabetic Complications
por: Yanai, Hidekatsu, et al.
Publicado: (2023)

GIP and GLP‐1, the two incretin hormones: Similarities and differences
por: Seino, Yutaka, et al.
Publicado: (2010)

The journey to understanding incretin systems: Theory, practice and more theory
por: Yabe, Daisuke, et al.
Publicado: (2019)

Cardiovascular safety trials of incretin‐based drugs: What do they mean?
por: Yabe, Daisuke, et al.
Publicado: (2016)

Incretin secretion stimulated by ursodeoxycholic acid in healthy subjects
por: Murakami, Masanori, et al.
Publicado: (2013)

Optical Control of Insulin Secretion Using an Incretin Switch
por: Broichhagen, Johannes, et al.
Publicado: (2015)

Chylomicrons stimulate incretin secretion in mouse and human cells
por: Psichas, Arianna, et al.
Publicado: (2017)

The Incretin Effect in Female Mice With Double Deletion of GLP-1 and GIP Receptors
por: Ahrén, Bo, et al.
Publicado: (2019)

Incretin concept revised: The origin of the insulinotropic function of glucagon‐like peptide‐1 – the gut, the islets or both?
por: Yabe, Daisuke, et al.
Publicado: (2017)

Molecular mechanisms underlying nutrient detection by incretin-secreting cells
por: Reimann, Frank
Publicado: (2010)

Intestinal organoids for assessing nutrient transport, sensing and incretin secretion
por: Zietek, Tamara, et al.
Publicado: (2015)

Improving the Effects of Imeglimin on Endothelial Function: A Prospective, Single-Center, Observational Study
por: Uchida, Taisuke, et al.
Publicado: (2023)

Incretin‐based drugs for type 2 diabetes: Focus on East Asian perspectives
por: Seino, Yutaka, et al.
Publicado: (2016)

Imeglimin: A Potential New Multi-Target Drug for Type 2 Diabetes
por: Vuylsteke, Valerie, et al.
Publicado: (2015)

Mechanism of action of Imeglimin: A novel therapeutic agent for type 2 diabetes
por: Hallakou‐Bozec, Sophie, et al.
Publicado: (2020)

Development of Imeglimin Electrospun Nanofibers as a Potential Buccal Antidiabetic Therapeutic Approach
por: Alamer, Ali A., et al.
Publicado: (2023)

Letter to the Editor: Can Imeglimin Improve the Systolic Time Intervals in Diabetes Mellitus?
por: Nishikawa, Tomoaki, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_4rokn82e6qv6h9ikfdiigj3up7